Posted by Michael Wonder on 01 Aug 2022
TGA approves new medicine for NSCLC patients with an EGFR exon 20 mutation
1 August 2020 - First medicine approved by the TGA for this mutation.
Mobocertinib (Exkivity) has provisional approval for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that has an exon 20 insertion mutation of the epidermal growth factor receptor, who have received prior platinum-based chemotherapy.
